A Study on the efficacy of Ayurvedic therapies like Jeevantyadi Taila Nasya, Shatahwadi Ghrita Tarpana along with oral intake of Rasayana Ghana Vati in the management of Age related Vision loss as compared to the prevalent multivitamin supplement therapy.

A Randomized Controlled Clinical Trial to Evaluate the Efficacy of Jeevantyadi Taila Nasya,Shatahwadi Ghritha Tarpana and Rasayana Ghana Vati oral intake in Vataja Timira with special reference to Dry Age related Macular Degeneration

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/01/100157

Enrollment

Registered

2026-01-01

Start date

Unknown

Completion date

Unknown

Last updated

2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H353- Degeneration of macula and posterior pole Health Condition 2: H353- Degeneration of macula and posterior pole

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients presenting with classical signs and symptoms of Vataja Timira i.e. blurred vision (Avila darshana), distorted vision (Vyavidham darshana), central scotoma (Pashyathi asyam anasikam), metamorphopsia (Vakram riju api manyate) 2.Early to intermediate forms of Dry AMD ie presence of Drusens and AMD changes in retina.

Exclusion criteria

Exclusion criteria: 1. Presence of any other retinal or macular pathology other than Non-Exudative AMD such as Exudative AMD Diabetic retinopathy Central geographic atrophy Hemorrhagic condition of fundus or retinal fluid. 2. History of retinal laser or surgical therapy in study eye. 3. Contraindication of pupil dilatation in the study eye. 4. Mature cataract or media opacification in either eye which limits an adequate view of fundus. 5. Unable to maintain stable fixation for OCT imagining. 6. Patient having systemic disorders that may confound or alter the course of AMD. 7. Patients who are contraindicated for any of the trial or control drugs.

Design outcomes

Primary

Measure	Time frame
Changes in Drusen levelsTimepoint: 60 days	—

Secondary

Measure	Time frame
Changes in visual acuity (BCVA), Changes in Macular thicknessTimepoint: 60 days	—

Countries

India

Contacts

Public ContactDr Prabhakar Vardhan

National Institute of Ayurveda

shalakya007@gmail.com9461065960

Outcome results